Maven Securities LTD Makes New Investment in ADMA Biologics Inc $ADMA

Maven Securities LTD bought a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 35,000 shares of the biotechnology company’s stock, valued at approximately $513,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new stake in ADMA Biologics in the 3rd quarter valued at about $1,268,000. Virtus Advisers LLC raised its stake in shares of ADMA Biologics by 318.8% in the third quarter. Virtus Advisers LLC now owns 18,412 shares of the biotechnology company’s stock valued at $270,000 after acquiring an additional 14,016 shares in the last quarter. Mariner LLC boosted its stake in shares of ADMA Biologics by 32.0% in the 3rd quarter. Mariner LLC now owns 38,373 shares of the biotechnology company’s stock valued at $563,000 after buying an additional 9,297 shares during the period. Lido Advisors LLC lifted its stake in ADMA Biologics by 10.7% in the third quarter. Lido Advisors LLC now owns 16,478 shares of the biotechnology company’s stock worth $242,000 after acquiring an additional 1,599 shares during the last quarter. Finally, HighVista Strategies LLC purchased a new stake in shares of ADMA Biologics during the 3rd quarter worth $1,394,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Insider Activity

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer directly owned 466,600 shares in the company, valued at $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Steve Elms purchased 7,000 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was acquired at an average price of $15.67 per share, with a total value of $109,690.00. Following the completion of the acquisition, the director directly owned 2,038,730 shares in the company, valued at $31,946,899.10. The trade was a 0.34% increase in their position. The SEC filing for this purchase provides additional information. 3.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ADMA shares. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Wall Street Zen raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Finally, Zacks Research upgraded ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, ADMA Biologics currently has a consensus rating of “Buy” and a consensus price target of $32.00.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $16.15 on Wednesday. The firm’s 50-day simple moving average is $16.55 and its 200 day simple moving average is $16.69. The firm has a market capitalization of $3.85 billion, a PE ratio of 26.92 and a beta of 0.51. ADMA Biologics Inc has a 52 week low of $13.76 and a 52 week high of $25.67. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.20. The business had revenue of $139.16 million during the quarter, compared to analysts’ expectations of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The company’s revenue was up 18.4% on a year-over-year basis. During the same period last year, the company posted $0.46 EPS. On average, equities research analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.